Reactogenicity of a group A and C meningococcal polysaccharide bivalent vaccine

A total of 1 968 persons aged 18-20 years belonging to organized groups were immunized with different doses of polysaccharide meningococcal divaccine, groups A and C, by means of syringes and jet injectors under the conditions of a controlled epidemiological trial. Systemic reactions to the injection of the preparation were found to be absent. Local reactions manifested by inflammation, swelling and tenderness at the site of injection were faintly pronounced and disappeared in 48 hours, which is indicative of low reactogenicity of the preparation under study.     

A群C群脑膜炎球菌结合疫苗稳定性

目的评价A群C群脑膜炎球菌结合疫苗原液和成品的稳定性。方法分别将A群、C群脑膜炎球菌结合疫苗原液及A群C群脑膜炎球菌结合疫苗各选取连续3批,分别放置于37℃、20~25℃和2~8℃3种温度下,在一定的时间取样进行主要项目测定,在关键时间点进行全面检测。结果 A群结合疫苗原液于2~8℃保存9个月,20~25℃保存4周,37℃保存4 d;C群结合疫苗原液于2~8℃保存9个月,20~25℃保存6个月,37℃保存4周;A群C群脑膜炎球菌结合疫苗于2~8℃保存2年3个月,20~25℃保存6个月,37℃可以保存9周;各项检测指标均符合质量标准的要求。结论在2~8℃条件下,A群、C群脑膜炎球菌结合疫苗原液存放6个月,A群C群脑膜炎球菌结合疫苗存放2年,其质量稳定。     

C群脑膜炎球菌结合物小鼠免疫原性的研究

目的比较C群脑膜炎球菌多糖蛋白质结合物(简称结合物)的相对分子质量大小和免疫剂量对其在小鼠体内免疫原性的影响,为结合物的分子大小的质控和结合疫苗成品免疫剂量的选择提供实验依据。方法利用CDAP活化法制备C群脑膜炎球菌结合物,通过硫酸铵盐析进行纯化,然后利用Sepharose CL-4B凝胶过滤层析分析,并根据化学检测结果将结合物分为KD0-0.2(组分1)、KD0.2-0.4(组分2)、KD0.4-0.7(组分3)等3个不同相对分子质量组分,每份分别采用1.0μg、0.2μg的免疫剂量免疫小鼠,并对血清进行ELISA分析。结果采用1.0μg免疫剂量时,3种不同相对分子质量的C群脑膜炎球菌结合物均能产生较高水平的抗体,具有典型的加强效应,第2剂免疫即可产生高水平的抗体,而第2、3剂免疫后的抗体水平差异无统计学意义;采用0.2μg免疫剂量时,三种不同相对分子质量的C群脑膜炎球菌结合物只有在第3剂免疫后才能产生较高水平抗体,第1、2剂免疫后的抗体水平差异无统计学意义,组分1和组分2在第3剂免疫后产生的抗体水平优于组分3;对于相同相对分子质量结合物,用1.0μg免疫小鼠产生的抗体水平优于0.2μg免疫组,而且有显著的统计学意义。结论高剂量时,多糖相对分子质量大小对C群脑膜炎球菌结合物的免疫原性没有显著性影响;低剂量时,小相对分子质量结合物对其免疫原性有影响。同等相对分子质量时,1.0μg比0.2μg的免疫剂量可以激发更高的抗体水平。     

C群流脑多糖菌苗唾液酸含量测定试验

Ｃ群脑膜炎球菌多糖菌苗是我们近年开发的一种新制品,其中唾液酸（ＳＡ）是该制品的有效成份之一。为了严格控制该制品的质量,经反复试验,对比各种试验条件,选择出较理想的测定ＳＡ方法－改良法,该法与Ｓｖｅｎｎｅｒｈｏｌｍ氏法比较,其标准曲线变异系数（ｃｖ％）为０．０３％,低于Ｓｖｅｎｎｅｒｈｏｌｍ氏法（０．３１％）;其回收率平均为１００．６２％。与中检所方法比较,无显著差异（Ｐ〉０．０５）,对批样品进行６     

Recurrent localized outbreaks of group C meningococcal disease and selective vaccination programmes

Conclusions (1) The high attack rate indicates that one virulent strain was responsible for the outbreaks. (2) The first vaccination programme carried through was not efficient enough to irradicate group C meningococcal disease whereas extension of the programme to the whole high-risk group was successful.     

Correlation of group C meningococcal conjugate vaccine response with B- and T-lymphocyte activity

Despite the success of conjugate vaccination against meningococcal group C (MenC) disease, post-vaccination, some individuals still exhibit rapid waning of initially protective bactericidal antibody levels. The mechanism of this relative loss of humoral protection remains undetermined. In this report we have investigated the relationship between T- and B-cell activation and co-stimulation and the loss of protective antibody titers. We have found that healthy volunteers who lose protective MenC antibody levels one year after receipt of glycoconjugate vaccine exhibit no detectable cellular defect in polyclonal B- or T-cell activation, proliferation or the B-memory pool. This suggests that the processes underlying the more rapid loss of antibody levels are independent of defects in either initial T- or B-cell activation.     

Chemoenzymatic synthesis of immunogenic meningococcal group C polysialic acid-tetanus Hc fragment glycoconjugates

Vaccination with meningococcal glycoconjugate vaccines has decreased the incidence of invasive meningitis worldwide. These vaccines contain purified capsular polysaccharides attached to a carrier protein. Because of derivatization chemistries used in the process, conjugation of polysaccharide to protein often results in heterogeneous mixtures. Well-defined vaccines are needed to determine the relationship between vaccine structure and generated immune response. Here, we describe efforts to produce well-defined vaccine candidates by chemoenzymatic synthesis. Chemically synthesized lactosides were substrates for recombinant sialyltransferase enzymes from Camplyobacter jejuni and Neisseria meningitidis serogroup C. These resulting oligosialic acids have the same α(2-9) sialic acid repeat structure as Neisseria polysaccharide capsule with the addition of a conjugatable azide aglycon. The degree of polymerization (DP) of carbohydrate products was controlled by inclusion of the inhibitor CMP-9-deoxy-NeuNAc. Polymers with estimated DP?<?47 (median DP 25) and DP?<?100 (median DP 51) were produced. The receptor binding domain of the tetanus toxin protein (TetHc) was coupled as a carrier to the enzymatically synthesized oligosialic acids. Recombinant TetHc was derivatized with an alkyne squarate. Protein modification sites were determined by trypsin proteolysis followed by LC/MS-MS^E analysis of peptides. Oligosialic acid azides were conjugated to modified TetHc via click chemistry. These chemoenzymatically prepared glycoconjugates were reactive in immunoassays with specific antibodies against either group C polysaccharide or TetHc. Sera of mice immunized with oligosialic acid-TetHc glycoconjugates contained much greater levels of polysaccharide-reactive IgG than the sera of control mice receiving unconjugated oligosialic acids. There was no apparent difference between glycoconjugates containing oligosaccharides of DP?<?47 and DP?<?100. These results suggest that chemoenzymatic synthesis may provide a viable method for making defined meningococcal vaccine candidates.     

冻干A+C群脑膜炎球菌多糖疫苗安全性和免疫原性观察

为了评价冻干A+C群脑膜炎球菌多糖疫苗(MPV)的安全性和免疫原性,按随机、盲法的原则,评价疫苗免疫后不良反应发生率、抗体阳转率及抗体几何平均滴度(GMT)。将606名健康观察者分为2～5岁、6～12岁、13～17岁、18～60岁四个年龄组,结果显示,该疫苗全身反应发生率2.64%,局部反应发生率1.32%,四个年龄组疫苗免疫后杀菌抗体阳性率分别为100%、100%、99.3%和100%,免疫后A群杀菌抗体GMT分别为1:250.47、1:190.61、1:144.22和1:205.79,免疫后C群杀菌抗体GMT分别为1:273.33、1:551.18、1:788.26和1:809.81,冻干A+C群多糖疫苗在≥2岁人群中具有良好的安全性和免疫原性,建议推广使用A+C群MPV。     

薄膜过滤法在A群C群脑膜炎球菌多糖疫苗无菌检查中的应用

采用薄膜过滤法对A群C群脑膜炎球菌多糖疫苗的无菌检查方法进行验证.结果表明,薄膜过滤法具有取样量大,操作简便,污染几率小,能确保检验结果的准确性、有效性和重现性,该方法适用于A群C群脑膜炎球菌多糖疫苗的无菌检查方法.     

Characterization of group C meningococcal polysaccharide by light-scattering spectroscopy. III. Determination of molecular weight, radius of gyration, and translational diffusional coefficient.

Group-specific polysaccharides isolated by means of a cetavlon procedure are immunogenic in man and induce protective immunity against meningococcal meningitis. Minute quantities of the polymers in solution can act as vaccines. We now report the first characterization of a fractionated (C-1) group C polysaccharide in 0.4KM KCl and 0.05M sodium acetate by means of light-scattering spectroscopy. Independent measurements of refractive index increments, absolute scattered intensities, angular scattering intensities and line widths as a function of scattering angles and delay times at different concentrations using incident wavelengths of 632.8 nm from a He–Ne laser and of 488 nm from an argon–ion laser yield information on aggregation properties, molecular weight (M_r), radius of gyration 〈r⁰_g〉^1/2_z, translational diffusion coefficient 〈D〉⁰_z, and second virial coefficients A₂ and B₂ of C-1 polysaccharide. At relatively high ionic strength (0.04M KCl + 0.05M sodium acetate), we obtain for the C-1 polysaccharide in solution M_r = 5.15 × 10⁵, 〈r²_g〉^1/2_z = 345 Å, A₂ = 1.25 × 10^?4 ml/g, 〈D〉 = 1.16 × 10^?7 cm²/sec with a corresponding Stokes radius of 240 Å and B₂ = 4.4 ml/g. A₂ and B₂ are the second virial coefficients from intensity- and diffusion-coefficient measurements. The C-1 polysaccharide aggregates in solution and behaves hydrodynamically like random coils. Viscosity and sedimentation studies further confirm our conclusions that the fractioned C-1 polysaccharide aggregates in solution and EDTA can partially break up those aggregates. However, the system remains polydisperse even after adding an excess amount of EDTA. The weight-average molecular weight of the C-1 polysaccharide in solution depends upon ionic strength and exhibits a minimum at ～0.2M KCl. Finally, viscosity, light-scattering, and sedimentation results all show that the aggregated macromolecular system behaves like random-coiled polymers with no measurable shape factors.     

Humoral immune response in animals after the oral administration of group C meningococcal whole-culture preparation

Experimental data giving grounds for the development of a new group C meningococcal whole-culture preparation for oral administration are presented. The study revealed that the use of the controlled cultivation of group C meningococci and a nutrient medium with definite chemical composition in combination with the "soft" method of the isolation of the whole-culture preparation ensured the preservation of polysaccharide, outer membrane protein and lipooligosaccharide in a native state, as well as retaining their full antigenic value, in the preparation. The oral immunization with the whole-culture preparation stimulated the multiple elevation of the level of hemagglutinating and IgG antibodies to these antigens and their prolonged preservation in the blood of immunized animals.     

HPLC法测定A群C群脑膜炎球菌多糖疫苗中乳糖含量

建立了高效液相色谱法测定A群C群脑膜炎球菌多糖疫苗中乳糖的含量。样品经离心除去多糖后,采用阳离子交换柱分离,外标法定量分析。该法线性相关系数大于0.9999,回收率为98.8%,成品测定的CV值为1.2%(<2%),该法定量准确,重复性好,适于对A群C群脑膜炎球菌多糖疫苗中乳糖含量进行快速检测。     

干烤法测定C群脑膜炎球菌多糖原液固体总量的不确定度评定

目的建立干烤法测定C群脑膜炎球菌多糖原液固体总量的不确定度分析方法。方法分析C群脑膜炎球菌多糖原液固体总量测定过程中引入的不确定度,并对各个不确定度的分量进行评估。结果由各分量不确定度计算合成不确定度,最终给出测定结果在95%置信区间的扩展不确定度。结论 C群脑膜炎球菌多糖原液固体总量测量不确定度主要由取样及干燥过程引入,在试验中须严格控制以减小不确定度。     

不同的甲醛杀菌浓度对A群、C群脑膜炎球菌荚膜多糖内毒素含量的影响

目的研究不同的甲醛杀菌浓度对A群、C群脑膜炎球菌荚膜多糖内毒素含量的影响。方法将A群脑膜炎球菌发酵液分成A、B两组,A组采用体积分数为2.5%甲醛杀菌,B组采用体积分数为2.0%甲醛杀菌。将C群脑膜炎球菌发酵液分成C、D两组,C组采用体积分数为2.5%甲醛杀菌,D组采用体积分数为2.0%甲醛杀菌。分别纯化获得荚膜多糖,用动态浊度法测定荚膜多糖中内毒素的含量。结果 A、C两组荚膜多糖中内毒素含量显著低于B、D两组荚膜多糖中的内毒素含量(P<0.05)。结论使用不同浓度的甲醛杀菌,对A群、C群脑膜炎球菌荚膜多糖内毒素的含量有显著影响。较高浓度的甲醛利于菌体细胞的固定,从而防止细菌自溶释放内毒素,因而高浓度的甲醛能够减少其内毒素的含量,提高了产品质量。